Home
HelpTest Code SOFT: Z1000 Methotrexate, Serum
Additional Codes
| Ordering Mnemonic | Mayo ID |
| EPIC NAME: MISC. LAB TEST | MTHX |
| EPIC CODE: LAB000 |
Reporting Name
Methotrexate, SUseful For
Determining whether methotrexate is being cleared appropriately and verifying that a nontoxic concentration has been attained following therapy
Method Name
Immunoassay
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SerumOrdering Guidance
For patients that have received glucarpidase (carboxypeptidase G2) as a high-dose methotrexate rescue therapy, order MTXSG / Methotrexate Post Glucarpidase, Serum.
Shipping Instructions
Ship specimen in amber vial to protect from light.
Specimen Required
Supplies: Sarstedt 5 mL Aliquot Tube (Amber) (T915)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Amber vial
Specimen Volume: 0.5 mL
Collection Instructions:
1. Methotrexate is sensitive to fluorescent light; avoid prolonged exposure of specimen to direct light.
2. Serum gel tubes should be centrifuged within 2 hours of collection. Protect from light.
3. Red-top tubes should be centrifuged and serum aliquoted into amber vial within 2 hours of collection.
Specimen Minimum Volume
0.25 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 14 days | LIGHT PROTECTED |
| Frozen | 28 days | LIGHT PROTECTED | |
| Ambient | 72 hours | LIGHT PROTECTED |
Reject Due To
| Gross hemolysis | Reject |
Reference Values
Nontoxic drug concentration after 72 hours: <0.1 mcmol/L
Day(s) Performed
Monday through Sunday
CPT Code Information
80204
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MTHX | Methotrexate, S | 14836-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| MTHX | Methotrexate, S | 14836-1 |
Clinical Information
Methotrexate is an antineoplastic agent that inhibits DNA synthesis. The medication exerts its effects through competitive inhibition of the enzyme dihydrofolate reductase thus decreasing the concentrations of tetrahydrofolate essential to the methylation of pyrimidine nucleotides and consequently the rate of pyrimidine nucleotide and ultimately DNA synthesis.
Methotrexate is used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Methotrexate is effective against malignancies characterized by rapid cell proliferation. Intermediate to high doses of methotrexate with leucovorin (citrovorum-factor or folinic acid) rescue to salvage nontumor cells have been used with favorable results in the treatment of osteogenic sarcoma, leukemia, non-Hodgkin lymphoma, lung, and breast cancer.
Methotrexate has the potential for serious toxicity. Patients undergoing methotrexate therapy are closely monitored so that toxic effects are detected promptly.
Interpretation
Serum concentrations of methotrexate are commonly monitored during high-dose therapy (>50 mg/m[2]) to identify the time at which active intervention by leucovorin rescue should be initiated. Criteria for serum concentrations indicative of a potential for toxicity after single-bolus, high-dose therapy are as follows:
-Methotrexate >10 mcmol/L 24 hours after dose
-Methotrexate >1 mcmol/L 48 hours after dose
-Methotrexate >0.1 mcmol/L 72 hours after dose
Cautions
Important: Specimens from patients who have received glucarpidase (carboxypeptidase G2) as a high-dose methotrexate rescue therapy should not be tested with this immunoassay. Methotrexate concentrations should be performed using the liquid chromatography-tandem mass spectrometry method to avoid the reporting of falsely elevated methotrexate values due to an interference that could confuse the efforts of the glucarpidase therapy. After glucarpidase therapy, it can take at least 5 to 7 days before accurate measurements of serum methotrexate can be obtained using an immunoassay.
Clinical Reference
1. Snozek CLH, McMillin GA, Moyer TP: Therapeutic drugs and their management. In Tietz Textbook of Clinical Chemistry. Fifth edition. Edited by CA Burtis, ER Ashwood, D Bruns. Philadelphia, WB Saunders Company, 2012, pp 1057-1108
2. Cadman EC, Durivage HJ: Cancer chemotherapy: alkylating agents. In Harrison's Principles of Internal Medicine. 12th edition. Edited by JD Wilson, E Braunwald, KJ Isselbacher, et al. New York, McGraw-Hill Book Company, 1991, pp 1592-1594
Method Description
The ARK Methotrexate Assay is a homogeneous immunoassay based on competition between drug in the specimen and methotrexate labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for binding to the antibody reagent. As the latter binds antibody, enzyme activity decreases. In the presence of drug from the specimen, enzyme activity increases and is directly proportional to the drug concentration. Active enzyme converts the coenzyme nicotinamide adenine dinucleotide (NAD) to NADH (the reduced form of NAD) that is measured spectrophotometrically as a rate of change in absorbance. Endogenous serum G6PDH does not interfere with the results because the coenyzme NAD functions only with the bacterial enzyme used in the assay.(Package insert: ARK Methotrexate reagent, ARK Diagnostics, Inc., Fremont, CA)
Report Available
Same day/1 daySpecimen Retention Time
1 weekTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.Forms
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.